Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Vercise Deep Brain Stimulation System

Boston Scientific news release; 2017 Dec 11

Boston Scientific Corporation has announced that it has received approval from the US Food and Drug Administration (FDA) for the Vercise Deep Brain Stimulation (DBS) System. DBS is used to treat the symptoms of Parkinson disease (PD), a degenerative condition that affects more than 1 million people in the US and 10 million worldwide. DBS works by stimulating a targeted region of the brain through implanted leads that are powered by a device called an implantable pulse generator (IPG). The approval was based on the INTREPID study, the first multi-center, prospective, double-blind, randomized sham-controlled study of DBS for PD in the US. The INTREPID study evaluated the safety of the system in 292 patients at 23 sites and also evaluated its effectiveness.

Boston Scientific is headquartered in Marlborough, MA.


Boston Scientific receives US FDA approval for the Vercise™ Deep Brain Stimulation System. Platform offers physicians advanced technology to treat symptoms of Parkinson's disease. [news release]. Marlborough, MA: Boston Scientific Corporation. December 11, 2017. Accessed January 2, 2018.

This Week's Must Reads

Hospital Readmission After Seizure Discharge, Neurology; ePub 2018 Dec 21; Blank, et al

VP Shunts and Post-Operative Complications Assessed, J Stroke Cerebrovasc Dis; ePub 2018 Dec 20; Linzey, et al

Disparities in Inter-Hospital Helicopter Transport, J Stroke Cerebrovasc Dis; ePub 2018 Dec 11; Sarrazin, et al

Mild-to-Moderate OSA Linked with Hypertension, Sleep; ePub 2018 Dec 22; Vgontzas, et al

Aspirin Reduces Stroke Risk in Women with Prior HDP, Neurology; ePub 2018 Dec 26; Miller, Boehme, et al

Must Reads in FDA Actions

FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23